Anthem Biosciences has raised ₹1,016 crore from anchor investors ahead of its upcoming IPO, which is set to open for public subscription on July 14 and close on July 16.
According to a circular uploaded on BSE’s website late Friday, the company has allotted 1.78 crore equity shares to 60 anchor investors at ₹570 per share—the upper end of the price band. As a result, the total transaction value amounts to ₹1,016 crore.
Prominent investors who participated in the anchor round include the Abu Dhabi Investment Authority, Government Pension Fund Global, Eastspring Investments, Amundi Funds, PineBridge Global Funds, and Societe Generale, along with domestic mutual funds such as HDFC MF, ICICI Prudential MF, Axis MF, UTI MF, Quant MF, and Motilal Oswal MF.
The ₹3,395 crore IPO by the Bengaluru-based Anthem Biosciences is entirely an offer-for-sale (OFS), meaning the company will not receive any proceeds; instead, the funds will go to the selling shareholders. Anthem Biosciences has set the IPO price band between ₹540 and ₹570 per share.
Anthem Biosciences operates as a technology-driven Contract Research, Development, and Manufacturing Organization (CRDMO) with end-to-end capabilities across drug discovery, development, and production. The company also manufactures and markets complex fermentation-based Active Pharmaceutical Ingredients (APIs) such as probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars.
Its listed peers include Sai Life Sciences Ltd, Syngene International, Suven Life Sciences, and Divi’s Laboratories.
JM Financial, Citigroup Global Markets India, J.P. Morgan India, and Nomura Financial Advisory and Securities (India) are acting as the book-running lead managers for the issue.
